Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Hammel · SciRah

Researcher profile · Semantic Scholar

P. Hammel

Share profile

P. Hammel — researcher profile on SciRah

h-index: 5
Works: 8
Citations: 180

Most-cited papers

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
E. O'Reilly, Z. Wainberg, A. Hendifar, M. Borad +16 more
2026New England Journal of Medicine99 citations
Semantic Scholar
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.
N. Fraunhoffer, P. Hammel, T. Conroy, R. Nicolle +21 more
2024Annals of Oncology41 citations Open access
Semantic Scholar
LBA62 Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44
A. Lambert, O. Bouché, A. Ayav, J. Bachet +9 more
2024Annals of Oncology30 citations
Semantic Scholar
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.
B. Wolpin, Z. Wainberg, A. Hendifar, M. Borad +16 more
2026Journal of Clinical Oncology10 citations
Semantic Scholar
Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial.
T. Golan, P. Hammel, M. Reni, E. Van Cutsem +15 more
2019Annals of Oncology5 citations Open access
Semantic Scholar
471TiP RASolute 303: A phase III global, multicenter, open-label, randomized 3-arm study of daraxonrasib monotherapy or daraxonrasib plus gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel as a first line treatment for patients with metastatic pancreatic adenocarcinoma
T. Seufferlein, P. Hammel, F. Pietrantonio, N. S. Azad +7 more
2026Annals of Oncology1 citations
Semantic Scholar
Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis
N. Tissera, M. Chiaravalli, A. Turpin, R. Luca +11 more
2023ESMO gastrointestinal oncology1 citations Open access
Semantic Scholar
Reply to the Letter to the Editor 'AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma' by Y. Shimazu.
N. Fraunhoffer, P. Hammel, J. Iovanna, N. Dusetti
2024Annals of Oncology0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. O'Reilly×2
Invite
E. O'Reilly — researcher profile on SciRah
Z. Wainberg×2
Invite
Z. Wainberg — researcher profile on SciRah
A. Hendifar×2
Invite
A. Hendifar — researcher profile on SciRah
M. Borad×2
Invite
M. Borad — researcher profile on SciRah

×2

Invite

Shubham Pant — researcher profile on SciRah

Paul E. Oberstein×2

Invite

Paul E. Oberstein — researcher profile on SciRah

Ignacio Garrido-Laguna×2

Invite

Ignacio Garrido-Laguna — researcher profile on SciRah

C. Springfeld×2

Invite

C. Springfeld — researcher profile on SciRah

Invite

N. Azad — researcher profile on SciRah

Invite

Makoto Ueno — researcher profile on SciRah

Invite

S. Chui — researcher profile on SciRah

Invite

Ying Zhang — researcher profile on SciRah